Engineered immune cells take on aggressive MS in first human trial
NCT ID NCT07178431
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tests a new treatment called MB-CART 2019.1 for people with active multiple sclerosis (MS) that hasn't responded to other therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack harmful immune cells driving MS. The goal is to see if it is safe and can stop disease activity, including relapses, worsening disability, and new brain lesions. About 26 adults with progressive MS will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité Universitätsmedizin Berlin
RECRUITINGBerlin, 13353, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.